Nasopharyngitis ( @ -LSB- @ % -RSB- patients receiving benralizumab vs @ -LSB- @ % -RSB- patients receiving placebo ) and injection site reactions ( @ -LSB- @ % -RSB- vs eight -LSB- @ % -RSB- ) occurred more frequently with benralizumab than with placebo .